Table 3.
Multivariate analysis for response and survival.
| Value | ORR | OS | ||||
|---|---|---|---|---|---|---|
| RR | 95% CI | P value | RR | 95% CI | P value | |
| Age, years | ||||||
| <65 | ||||||
| ≥65 | 1.021 | 0.350–2.980 | 0.970 | |||
| ALC, ×109/L | ||||||
| <1.0 | ||||||
| ≥1.0 | 0.362 | 0.060–2.193 | 0.369 | |||
| ECOG (%) | ||||||
| 0-1 | ||||||
| ≥2 | 2.006 | 0.711–5.660 | 0.188 | 0.421 | 0.147–1.208 | 0.108 |
| Serum albumin, g/dL | ||||||
| <3.5 | ||||||
| ≥3.5 | 1.123 | 0.264–4.772 | 0.875 | |||
| ISS (%) | ||||||
| I | ||||||
| II | 0.439 | 0.078–2.486 | 0.352 | |||
| III | 0.209 | 0.066–0.665 | 0.008 | |||
| Treatment regimen | ||||||
| Novel agent combined chemotherapy | ||||||
| Conventional chemotherapy | 5.048 | 1.032–24.702 | 0.046 | 0.368 | 0.075–1.803 | 0.217 |
ORR: overall response rates; OS: overall survival rates; RR: relative risk; 95% CI: 95% confidence interval; ALC: absolute lymphocyte count; ECOG: Eastern Cooperative Oncology Group performance status; ISS: international staging system.